Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

9.4%

6 terminated/withdrawn out of 64 trials

Success Rate

81.8%

-4.7% vs industry average

Late-Stage Pipeline

6%

4 trials in Phase 3/4

Results Transparency

15%

4 of 27 completed trials have results

Key Signals

13 recruiting4 with results6 terminated

Enrollment Performance

Analytics

N/A
23(39.7%)
Phase 2
16(27.6%)
Phase 1
15(25.9%)
Phase 4
2(3.4%)
Phase 3
2(3.4%)
58Total
N/A(23)
Phase 2(16)
Phase 1(15)
Phase 4(2)
+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (64)

Showing 20 of 64 trials
NCT06812858Phase 2Recruiting

PD-1 Inhibitors Maintenance for cHL Post-autoHCT

Role: lead

NCT07548866Active Not Recruiting

Comparison of Laryngeal Mask and Tracheal Intubation With and Without Topical Lidocaine Application

Role: lead

NCT07234487Phase 2Recruiting

Comparison of AVD + Low-Dose Nivolumab vs. PET-Adapted BEACOPP-like in Advanced cHL

Role: lead

NCT03157258Not ApplicableCompleted

Social Network Intervention to Engage Community PLH to Engage in HIV Medical Care

Role: collaborator

NCT07238712Phase 2Recruiting

Optimization of Post-transplantation Benadamustine and Cyclophosphamide in Patients With High-risk Myeloid Malignancies and a Partially Mismatched Donor

Role: lead

NCT07074951Not ApplicableRecruiting

Tonsillectomy and Immunosuppression in Caucasian Patients With High-risk IgA-nephropathy

Role: lead

NCT04669210Phase 2Completed

PTCy and Ruxolitinib vs PTCy, Tacrolimus and MMF in MUD and Haploidentical HSCT

Role: lead

NCT06931613Phase 2Enrolling By Invitation

Autologous Hematopoietic Stem Cell Transplantation in Pediatric Relapsed or Refractory Hodgkin Lymphoma After Nivolumab Treatment

Role: lead

NCT03692715Phase 4Completed

Antibiotic Prophylaxis Before Shock Wave Lithotripsy

Role: collaborator

NCT06871007Phase 1Enrolling By Invitation

Nivolumab and DA-EPOCH-R in Pediatric Primary Mediastinal (Thymic) Large B-cell Lymphoma

Role: lead

NCT05311514Phase 2Completed

Allogeneic Platelet Lysate Eye Drops for the Treatment of Severe Chronic Ocular Graft-versus-host Disease

Role: lead

NCT04269850Phase 1Terminated

Fecal Microbiota Transplantation With Ruxolitinib and Steroids as an Upfront Treatment of Severe Acute Intestinal GVHD

Role: lead

NCT04943757Phase 2Completed

Post-transplantation Benadamustine and Cyclophosphamide in Patients With Refractory Myeloid Malignancies

Role: lead

NCT06532084Phase 2Recruiting

Sorafenib Relapase Prophylaxis After HCT With PTBCy Regimen

Role: lead

NCT06508099Phase 2Recruiting

Vitamin A and D Supplementation in Allogeneic HCT

Role: lead

NCT06477549Phase 2Recruiting

BeFluBu vs FluBuRux Conditioning in Haploidentical HCT

Role: lead

NCT05009719Phase 1Completed

Risk-adapted Donor Lymphocyte Infusion After Allo-HSCT in Children With Hematologic Malignancy

Role: lead

NCT06418776Phase 3Recruiting

IMPACT-AML: Randomized Pragmatic Clinical Trial for Relapsed or Refractory AML

Role: collaborator

NCT04452175Not ApplicableRecruiting

Cigarette Consumption After switchinG to High or Low Nicotine strENght E-cigaretteS In Smokers With Schizophrenia

Role: collaborator

NCT03292263Phase 1Active Not Recruiting

ASCT With Nivolumab in Patients With Multiple Myeloma

Role: lead